TECON BIOLOGY Co.LTD (002100) Fundamentals 2026 — Revenue Analysis | SniperIQ
TECON BIOLOGY Co.LTD (002100) is a CN-listed Consumer Defensive company in Packaged Foods with a market capitalization of ¥9.7B, trading at ¥7.13 on the SHZ. This SniperIQ fundamentals page covers TECON BIOLOGY Co.LTD's valuation, profitability (net margin -0.6%), revenue (¥17.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is TECON BIOLOGY Co.LTD's market cap?
TECON BIOLOGY Co.LTD (002100) has a market capitalization of approximately ¥9.7B, trading at ¥7.13 on the SHZ. Market cap moves with the live share price.
What is TECON BIOLOGY Co.LTD's P/E ratio?
TECON BIOLOGY Co.LTD's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is TECON BIOLOGY Co.LTD?
TECON BIOLOGY Co.LTD runs a net profit margin of -0.6%, a gross margin of 7.9%, and an operating margin of 0.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does TECON BIOLOGY Co.LTD generate?
TECON BIOLOGY Co.LTD reported revenue of ¥17.0B for fiscal year 2025, with net income of ¥211M and earnings per share (EPS) of 0.15. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does TECON BIOLOGY Co.LTD pay a dividend?
TECON BIOLOGY Co.LTD offers a trailing dividend yield of about 1.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is TECON BIOLOGY Co.LTD financially healthy?
TECON BIOLOGY Co.LTD carries a debt-to-equity ratio of 0.83x and a current ratio of 1.63x, with a market beta of 0.57. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is TECON BIOLOGY Co.LTD a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For TECON BIOLOGY Co.LTD (002100) the key facts are: market cap ¥9.7B, revenue ¥17.0B, 52-week range 5.64-8.46. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track TECON BIOLOGY Co.LTD's full fundamentals live
Get TECON BIOLOGY Co.LTD's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.